Highridge Medical Divests Bone Healing Division to Focus on Core Spine Technologies
核心洞察
Highridge Medical (搜索) has completed the sale of its EBI Bone Healing Division (搜索) to Avista Healthcare Partners (搜索) as part of a strategic refocusing on core spine solutions.
The divested division specializes in non-invasive bone stimulation devices (搜索) for spinal and orthopedic patients and will now operate as an independent company.
Highridge plans to use proceeds from the sale to drive long-term growth of its spine portfolio and accelerate innovation in surgical technologies.
Highridge Medical (搜索), one of the world's largest privately held spine companies, has completed the strategic divestiture of its EBI Bone Healing Division (搜索) to Avista Healthcare Partners (搜索), marking a pivotal shift toward exclusive focus on spinal technologies. The transaction, announced June 4, 2025, represents a calculated move by the global medical device manufacturer to concentrate resources on its core spine solutions and accelerate innovation in surgical technologies.
Strategic Refocusing on Spine Technologies
The divested EBI division, based in Parsippany, New Jersey, operates as a leading provider of non-invasive bone stimulation devices (搜索) for spinal and orthopedic patients. The division specializes in noninvasive and implantable bone growth stimulation therapies for spine, orthopedics and podiatrists, and will now function as an independent company under new ownership.
"Divesting the bone healing division allows Highridge to further sharpen our focus on our most promising growth opportunities," said Rebecca Whitney, CEO of Highridge Medical (搜索). "We are committed to driving innovation in partnership with our surgeon customers to deliver innovative spinal solutions to enhance patient outcomes."
Investment Strategy and Market Position
H.I.G. Capital (搜索), the leading global alternative investment firm with $70 billion of capital under management that owns Highridge, initially acquired EBI as part of the Highridge take-private transaction in April 2024. Following the acquisition, H.I.G. made several significant investments in EBI, including the addition of new senior leadership and expanded product development capabilities.
Mike Gallagher, Managing Director at H.I.G., emphasized the strategic rationale behind the transaction: "This transaction allows us to make significant investments in Highridge's core spine business, where we see tremendous opportunities to lead the next generation of spine care through continued focus on innovation and exceptional patient outcomes."
Leadership Transition and Future Outlook
Glen Kashuba, CEO of EBI, expressed confidence in the division's future prospects under new ownership. "This next chapter presents an exciting opportunity to broaden the Company's impact by delivering proven bone healing technologies to even more patients," Kashuba stated. "EBI remains deeply committed to advancing care, supporting our clinical partners, and driving meaningful, life-changing outcomes."
Highridge Medical (搜索) maintains its position as a global medical device company committed to improving spine care through surgeon partnerships and innovation. The company's portfolio includes solutions for complex spine, motion preservation, and minimally invasive surgery, all supported by extensive clinical evidence.
Transaction Details
While specific financial terms of the sale were not disclosed, Highridge plans to utilize the proceeds to drive long-term growth of its spine portfolio and enhance commercial capabilities. Robert W. Baird & Co. (搜索) served as financial advisor and McDermott Will & Emery LLP (搜索) acted as legal advisor to H.I.G. Capital (搜索) in connection with the transaction.
The divestiture positions both entities for focused growth in their respective markets, with EBI continuing its mission in bone healing technologies while Highridge concentrates on advancing spinal care solutions.